ArticleAnnals of Ibadan postgraduate medicine2025
HUMAN IMMUNODEFICIENCY VIRUS IN CERVICAL CANCER PATIENTS TREATED WITH RADIOTHERAPY IN IBADAN, NIGERIA; A REVISIT.
Article in Annals of Ibadan postgraduate medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer and human immunodeficiency virus are diseases of public health concern as they both have debilitating effects on human health. Human immunodeficiency virus worsens the carcinogenicity of HPV, thereby elevating the risk of cervical cancer. A previous study conducted at our center two decades ago reported a low prevalence of HIV among cervical cancer patients. Objective: This study is aimed at determining the current prevalence of HIV among patients with cervical cancer presenting for radiation treatment and comparing it with our previous findings 20 years earlier in order to assess changes in epidemiological trends. Methods: A retrospective analysis of patients with histologic diagnosis of cervical cancer seen between 2017 and 2019 was carried out. HIV statuses were determined using the Determine test kit for screening and Western blot for confirmation, and data was analyzed using appropriate statistical methods including the chi-square test for categorical variables and t-tests for continuous variables. P-values < 0.05 were considered statistically significant. Results: A total of 156 patients were seen with a mean age of 54.9± 11.4 years (range from 33-90 years). The prevalence of HIV was found to be 6.4%, slightly higher than our previous finding with prevalence of 2.7%. The HIV positive patients were younger (mean age 44.7 ± 6 years) than the HIV negative patients (55.14 ± 10.84 years) by about 10 years which was statistically significant (p=0.003). Most of the patients presented with an advanced disease, with 50% of the patients presenting with stage III disease, while 10% had stage IV disease. The HIV positive patients presented with more early stage (Stages I and II) diseases (60%). Squamous cell carcinoma was the most common histological type accounting for 89.7. Conclusion: As a follow up study, it appears that not much has changed from our previous findings as there.
Indexed as
Identifiers
41404081PMC12704350What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.